Laguna Hills, CA. (PRWEB) April 05, 2012
Patrick Maley, Chief Operating Officer of Apnea Sciences Corporation, announced that their breakthrough product ApneaRx TM was just approved by the FDA and is now available for the 20 million sleep apnea sufferers in America who think CPAP (continuous positive airway pressure mask pictured at right) is the only remedy for their disorder. Most of these sufferers are unaware that a much more patient friendly oral appliance (mouthpiece designed to treat sleep apnea) is recommended by the American Academy of Sleep Medicine as a first line treatment for less severe and non-compliant CPAP patients.
Maley said, “Up until now there has not been an affordable “transition” oral appliance that has been good enough to help the medical practitioner decide whether an oral appliance, or CPAP therapy is best for their patients. Our research indicates that effective oral appliance therapy would be preferred by most patients.”
ApneaRx TM (in picture) is the first thermal oral appliance that meets the New Medicare Product Standards of being adjustable by the patient in 1mm increments. What makes ApneaRx TM unique is that it does this without any moving parts, screws, metal rods or plastic bands used by much more expensive devices, or metal hardware that could compromise the patient.
ApneaRx TM will help the practitioner decide which treatment is best for their patient – custom oral appliance or CPAP. Oral appliance users are more compliant and CPAP therapy is more effective. Both therapies are successful 50-60% of the time and cost thousands of dollars. ApneaRx TM can reduce the cost risks associated with these therapies. It can be adjusted just like the more expensive custom oral appliances at a fraction of the cost to help determine clinical efficacy of oral appliances. If the ApneaRx TM treatment is successful, a more customized oral appliance can be prescribed. If not, CPAP should be used. Continued usage of ApneaRx TM is also a good economic alternative.
Patrick Wolcott, MD, Medical Director of The Sleep Center of Southern California in Encinitas, California commented that “ApneaRx TM provides the sleep clinician with an inexpensive way to determine the best treatment for their patients. In my practice, oral appliance therapy often leads to better compliance and a happier patient.”
Ed Spiegel, DDS, a prominent dentist specializing in sleep medicine in Scottsdale Arizona who lectures nationally, stated that “ApneaRx TM is a great advancement and will help give patients more piece of mind when choosing custom oral appliance therapy to reduce their sleep apnea.”
Maley commented, “The reception for ApneaRx TM has been overwhelming. The need for a “transition” oral appliance to help determine the best and most cost effective sleep apnea treatment is being driven by industry trends to contain health costs.”
Dr. Wolcott believes ApneaRx TM will be well received by the sleep apnea medical community.
About Apnea Sciences
After many years of research and development, Apnea Sciences has used its patent pending technology to build a pipeline of devices to address the large snoring and sleep apnea markets. During the last few months it has secured FDA Approval for SnoreRx TM and ApneaRx TM to treat snoring and sleep apnea respectably. For more information contact Patrick Maley, pmaley(at)apneasciences.com, 617 835 3757.